The Use of Tiagabine in Affective Disorders

We reviewed the available literature on the efficacy of a novel anticonvulsant, Tiagabine (TGB), in the treatment of bipolar disorder. Study results indicate that TGB does not represent a valid option in acute mania due its required slow, progressive titration. More rapid titration schemes may lead to severe complications. TGB may be an option as an adjunct long-term treatment approach in refractory patients, but further studies are clearly needed to support this.

References

• 1 Meldrum B S, Chapman A G. Basic mechanisms of gabitril (tiagabine) and future potential developments.  Epilepsia. 1999;  40 ((Suppl 9)) S 2-S 6
• 2 Suzdak P D, Jansen J A. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor.  Epilepsia. 1995;  36 612-626
• 3 Adkins J C, Noble S. Tiagabine a review of its pharmacodynamic and pharmacokinetic properties and terapeutic potential in the management of epilepsy.  Drugs. 1998;  55 437-460
• 4 Loiseau P. Review of controlled trials of gabitril (tiagabine): a clinician's viewpoint.  Epilepsia. 1999;  40 ((Suppl 9)) S 14-S 19
• 5 Krauss G, Carlson H A, Deaton R, Sommeville K W. Beneficial results of tiagabine therapy in patients with psychiatric history.  Epilepsia. 1997;  37 ((Suppl 8)) S 105
• 6 Leppik I E. Tiagabine the safety landscape.  Epilepsia. 1995;  36 ((Suppl 6)) S 10-S 13
• 7 Grunze H, Erfurth A, Marcuse A. Tiagabine appears not to be efficacious in the treatment of acute mania.  Journal of Clinical Psychiatry. 1999;  60 759-762
• 8 Schaffer L C, Schaffer C B. Tiagabine and the treatment of refractory bipolar disorder.  Am J Psychiatry. 1999;  156 2014-2015
• 9 Kaufman K R. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann. Clin.  Psychiatry. 1998;  10 181-184